US Patent
US9138456 — Lipopeptide compositions and related methods
Formulation · Assigned to Cubist Pharmaceuticals LLC · Expires 2030-11-23 · 5y remaining
Vulnerability score
48/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects novel powder formulations of daptomycin, such as those containing daptomycin and sucrose, with improved stability and reconstitution times.
USPTO Abstract
The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.
Drugs covered by this patent
- Cubicin (Daptomycin) · Baxter
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.